Description: <b>Honokiol</b> is a Lignan isolated from bark, seed cones and leaves of trees of Magnolia species. Honokiol was traditionally used for anxiety and stroke treatment, as well as the alleviation of flu symptoms.<br>
-considered to have antioxidant properties<br>
-low oral bioavailability and difficulty in intravenous administration<br>
-the development of various formulations of honokiol, including microemulsion, liposomes, nanoparticles and micelle copolymers have successfully solved the problem of low water solubility.<br>
<br>
Pathways:<br>
-Inhibit NF-κB activation<br>
-Downregulate STAT3 signalin<br>
-Inhibiting the PI3K/Akt pathway,<br>
-Inhibition of mTOR<br>
-Influences various MAPK cascades—including ERK, JNK, and p38<br>
-Inhibition of EGFR<br>
-Inhibiting Notch pathway (CSCs)<br>
-GPx4 inhibit<br>
-Can induce ER stress in cancer cells, which contributes to the activation of unfolded protein response (UPR) pathways<br>
-Disrupt the mitochondrial membrane potential in cancer cells.<br>
-Reported to increase ROS production in cancer cells<br>
-Can exhibit antioxidant properties in normal cells.
- has some inhibitor activity but Not classified as HDAC inhibitor as weaker and may work more indirectly.<br>
- is well-known in the research community for its role in activating SIRT3<br>
<br>
-Note <a href="tbResList.php?qv=94&tsv=1109&wNotes=on&exSp=open">half-life</a> 40–60 minutes<br>
<a href="tbResList.php?qv=94&tsv=792&wNotes=on&exSp=open">BioAv</a>
<br>
Pathways:<br>
<!-- ROS : MMP↓, ER Stress↑, Ca+2↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, UPR↑, cl-PARP↑-->
- induce
<a href="tbResList.php?qv=94&tsv=275&wNotes=on">ROS</a> production in cancer cells,
and typically lowers ROS in normal cells<br>
- ROS↑ related:
<a href="tbResList.php?qv=94&tsv=197&wNotes=on&word=MMP↓">MMP↓</a>(ΔΨm),
<a href="tbResList.php?qv=94&tsv=103&wNotes=on">ER Stress↑</a>,
<a href="tbResList.php?qv=94&tsv=356&wNotes=on">GRP78↑</a>,
<a href="tbResList.php?qv=94&tsv=38&wNotes=on&word=Ca+2↑">Ca+2↑</a>,
<a href="tbResList.php?qv=94&tsv=77&wNotes=on">Cyt‑c↑</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=Casp">Caspases↑</a>,
<a href="tbResList.php?qv=94&tsv=82&wNotes=on&word=DNAdam↑">DNA damage↑</a>,
<a href="tbResList.php?qv=94&tsv=239&wNotes=on">cl-PARP↑</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=HSP">HSP↓</a>
<a href="tbResList.php?qv=94&wNotes=on&word=Prx">Prx</a><!-- mitochondrial antioxidant enzyme-->
<br>
- Raises
<a href="tbResList.php?qv=94&tsv=1103&wNotes=on&word=antiOx↑">AntiOxidant</a>
defense in Normal Cells:
<a href="tbResList.php?qv=94&tsv=275&wNotes=on&word=ROS↓">ROS↓</a>,
<a href="tbResList.php?qv=94&tsv=226&wNotes=on&word=NRF2↑">NRF2↑</a>,
<a href="tbResList.php?qv=94&tsv=298&wNotes=on&word=SOD↑">SOD↑</a>,
<a href="tbResList.php?qv=94&tsv=137&wNotes=on&word=GSH↑">GSH↑</a>,
<a href="tbResList.php?qv=94&tsv=46&wNotes=on&word=Catalase↑">Catalase↑</a>,
<br>
<!-- INFLAMMATION : NF-kB↓, COX2↓, COX2↓ PRO-INFL CYTOKINES: IL-1β↓, TNF-α↓, IL-6↓, IL-8↓, -->
- lowers
<a href="tbResList.php?qv=94&tsv=953&wNotes=on&word=Inflam">Inflammation</a> :
<a href="tbResList.php?qv=94&tsv=214&wNotes=on&word=NF-kB↓">NF-kB↓</a>,
<a href="tbResList.php?qv=94&tsv=66&wNotes=on&word=COX2↓">COX2↓</a>,
Pro-Inflammatory Cytokines :
<a href="tbResList.php?qv=94&tsv=978&wNotes=on&word=IL1β↓">IL-1β↓</a>,
<a href="tbResList.php?qv=94&tsv=309&wNotes=on&word=TNF-α↓">TNF-α↓</a>,
<a href="tbResList.php?qv=94&tsv=158&wNotes=on&word=IL6↓">IL-6↓</a>,
<br>
<!-- GROWTH/METASTASES : EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1, uPA↓, VEGF↓, ERK↓
inhibiting metastasis-associated proteins such as ROCK1, FAK, (RhoA), NF-κB and u-PA, MMP-1 and MMP-13.-->
- inhibit Growth/Metastases :
<a href="tbResList.php?qv=94&tsv=604&wNotes=on">TumMeta↓</a>,
<a href="tbResList.php?qv=94&tsv=323&wNotes=on">TumCG↓</a>,
<a href="tbResList.php?qv=94&tsv=96&wNotes=on">EMT↓</a>,
<a href="tbResList.php?qv=94&tsv=204&wNotes=on">MMPs↓</a>,
<a href="tbResList.php?qv=94&tsv=201&wNotes=on">MMP2↓</a>,
<a href="tbResList.php?qv=94&tsv=203&wNotes=on">MMP9↓</a>,
<a href="tbResList.php?qv=94&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=94&tsv=1284&wNotes=on">ROCK1↓</a>,
<a href="tbResList.php?qv=94&tsv=273&wNotes=on">RhoA↓</a>,
<a href="tbResList.php?qv=94&tsv=214&wNotes=on">NF-κB↓</a>,
<a href="tbResList.php?qv=94&tsv=79&wNotes=on">CXCR4↓</a>,
<a href="tbResList.php?qv=94&tsv=105&wNotes=on">ERK↓</a>
<br>
<!-- REACTIVATE GENES : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, -->
- reactivate genes thereby inhibiting cancer cell growth :
<a href="tbResList.php?qv=94&tsv=140&wNotes=on">HDAC↓</a>,
<a href="tbResList.php?qv=94&tsv=108&wNotes=on">EZH2↓</a>,
<a href="tbResList.php?qv=94&tsv=236&wNotes=on">P53↑</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=HSP">HSP↓</a>,
<br>
<!-- CELL CYCLE ARREST : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓ -->
- cause Cell cycle arrest :
<a href="tbResList.php?qv=94&tsv=322&wNotes=on">TumCCA↑</a>,
<a href="tbResList.php?qv=94&tsv=73&wNotes=on">cyclin D1↓</a>,
<a href="tbResList.php?qv=94&tsv=378&wNotes=on">cyclin E↓</a>,
<a href="tbResList.php?qv=94&tsv=467&wNotes=on">CDK2↓</a>,
<a href="tbResList.php?qv=94&tsv=894&wNotes=on">CDK4↓</a>,
<a href="tbResList.php?qv=94&tsv=895&wNotes=on">CDK6↓</a>,
<br>
<!-- MIGRATION/INVASION : TumCMig↓, TumCI↓, FAK↓, ERK↓, -->
- inhibits Migration/Invasion :
<a href="tbResList.php?qv=94&tsv=326&wNotes=on">TumCMig↓</a>,
<a href="tbResList.php?qv=94&tsv=324&wNotes=on">TumCI↓</a>,
<a href="tbResList.php?qv=94&tsv=105&wNotes=on">ERK↓</a>,
<a href="tbResList.php?qv=94&tsv=96&wNotes=on">EMT↓</a>,
<br>
<!-- GLYCOLYSIS : ATP↓, HIF-1α↓, PKM2↓, cMyc↓, PDK1↓, GLUT1↓, LDHA↓, HK2↓, Glucose↓, GlucoseCon↓, lactateProd, OXPHOS -->
- inhibits
<a href="tbResList.php?qv=94&tsv=129&wNotes=on">glycolysis</a>
and
<a href="tbResList.php?qv=94&tsv=21&wNotes=on&word=ATP↓">ATP depletion</a> :
<a href="tbResList.php?qv=94&tsv=143&wNotes=on">HIF-1α↓</a>,
<a href="tbResList.php?qv=94&tsv=35&wNotes=on">cMyc↓</a>,
<a href="tbResList.php?qv=94&tsv=566&wNotes=on&word=GLUT">GLUT1↓</a>,
<a href="tbResList.php?qv=94&tsv=906&wNotes=on">LDH↓</a>,
<a href="tbResList.php?qv=94&tsv=175&wNotes=on&word=LDH">LDHA↓</a>,
<a href="tbResList.php?qv=94&tsv=773&wNotes=on">HK2↓</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=PDK">PDKs↓</a>,
<a href="tbResList.php?qv=94&tsv=847&wNotes=on">ECAR↓</a>,
<a href="tbResList.php?qv=94&tsv=230&wNotes=on">OXPHOS↓</a>,
<a href="tbResList.php?qv=94&tsv=356&wNotes=on">GRP78↑</a>,
<a href="tbResList.php?qv=94&tsv=623&wNotes=on">GlucoseCon↓</a>
<br>
<!-- ANGIOGENESIS : VEGF↓, VEGFR2↓, HIF-1α↓, NOTCH↓, FGF↓, PDGF↓, EGFR↓ ITG(Integrins↓)-->
- inhibits
<a href="tbResList.php?qv=94&tsv=447&wNotes=on">angiogenesis↓</a> :
<a href="tbResList.php?qv=94&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=94&tsv=143&wNotes=on">HIF-1α↓</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=NOTCH">Notch↓</a>,
<a href="tbResList.php?qv=94&tsv=94&wNotes=on&word=EGFR↓">EGFR↓</a>,
<br>
<!-- CSCs : CSC↓, CK2↓, Hh↓, GLi↓, GLi1↓, -->
- inhibits Cancer Stem Cells :
<a href="tbResList.php?qv=94&tsv=795&wNotes=on">CSC↓</a>,
<a href="tbResList.php?qv=94&tsv=677&wNotes=on">CD133↓</a>,
<a href="tbResList.php?qv=94&tsv=342&wNotes=on">β-catenin↓</a>,
<a href="tbResList.php?qv=94&tsv=656&wNotes=on">sox2↓</a>,
<a href="tbResList.php?qv=94&tsv=1024&wNotes=on">nestin↓</a>,
<a href="tbResList.php?qv=94&tsv=508&wNotes=on">OCT4↓</a>,
<br>
<!-- OTHERS : -->
- Others: <a href="tbResList.php?qv=94&tsv=252&wNotes=on">PI3K↓</a>,
<a href="tbResList.php?qv=94&tsv=4&wNotes=on">AKT↓</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=JAK">JAK↓</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=STAT">STAT↓</a>,
<a href="tbResList.php?qv=94&tsv=377&wNotes=on">Wnt↓</a>,
<a href="tbResList.php?qv=94&tsv=342&wNotes=on">β-catenin↓</a>,
<a href="tbResList.php?qv=94&tsv=9&wNotes=on">AMPK</a>,
<a href="tbResList.php?qv=94&tsv=105&wNotes=on">ERK↓</a>,
<a href="tbResList.php?qv=94&tsv=168&wNotes=on">JNK</a>,
<a href="tbResList.php?qv=94&wNotes=on&word=Trx">TrxR**</a>,
- Shown to modulate the nuclear translocation of
<a href="tbResList.php?qv=94&tsv=1132&wNotes=on&exSp=open&word=SREBP2">SREBP-2</a> (related to cholesterol).<br>
<!-- SYNERGIES : -->
- Synergies:
<a href="tbResList.php?qv=94&tsv=1106&wNotes=on">chemo-sensitization</a>,
<a href="tbResList.php?qv=94&tsv=1171&wNotes=on">chemoProtective</a>,
<a href="tbResList.php?qv=94&tsv=1107&wNotes=on">RadioSensitizer</a>,
<a href="tbResList.php?qv=94&tsv=1185&wNotes=on">RadioProtective</a>,
<a href="tbResList.php?qv=94&tsv=961&esv=2&wNotes=on&exSp=open">Others(review target notes)</a>,
<a href="tbResList.php?qv=94&tsv=1105&wNotes=on">Neuroprotective</a>,
<a href="tbResList.php?qv=94&tsv=557&wNotes=on">Cognitive</a>,
<a href="tbResList.php?qv=94&tsv=1175&wNotes=on">Renoprotection</a>,
<a href="tbResList.php?qv=94&tsv=1179&wNotes=on">Hepatoprotective</a>,
<a href="tbResList.php?&qv=94&tsv=1188&wNotes=on">CardioProtective</a>,
<br>
<br>
<!-- SELECTIVE: -->
- Selectivity:
<a href="tbResList.php?qv=94&tsv=1110&wNotes=on">Cancer Cells vs Normal Cells</a><br>
<br>
<p><b>Honokiol</b> — a small, lipophilic biphenolic neolignan isolated principally from the bark, seed cones, and leaves of <i>Magnolia</i> species, especially <i>Magnolia officinalis</i>. It is a natural-product small molecule rather than a standardized Magnolia extract; the standard abbreviation is HNK. Honokiol crosses biological membranes readily and has documented CNS penetration, but its pharmaceutical development is constrained by extremely poor aqueous solubility, rapid metabolism, and low/variable oral systemic exposure. Cancer research is dominated by cell and animal studies, although an oral Phase I window-of-opportunity study in patients with resectable early-stage non-small-cell lung cancer is now enrolling.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Mitochondrial targeting and respiratory Complex I inhibition, producing mitochondrial dysfunction, loss of membrane potential, energetic stress, and intrinsic apoptosis in susceptible cancer cells.</li>
<li>Suppression of oncogenic survival signaling, particularly STAT3 and PI3K/AKT/mTOR, with additional inhibition of EGFR and context-dependent MAPK signaling.</li>
<li>Induction of mitochondrial ROS and oxidative stress in cancer cells as a major stress-amplifying mechanism; in nonmalignant tissues honokiol can instead activate antioxidant and mitochondrial-protective programs including SIRT3 and NRF2.</li>
<li>Suppression of NF-κB-dependent inflammatory and prosurvival transcription, contributing to apoptosis, reduced inflammatory signaling, and treatment sensitization.</li>
<li>Suppression of EMT, migration, invasion, cancer-stem-cell phenotypes, and angiogenic signaling through STAT3, Wnt/β-catenin, EGFR, HIF-1α, VEGF, Snail/Slug, MMPs, and related networks.</li>
<li>Metabolic inhibition, including suppression of HIF-1α-driven glycolysis, GLUT1, HK2, LDHA and PDK signaling, with reduced glycolytic flux and ATP availability in several tumor models.</li>
<li>Induction of ER stress, autophagy, cell-cycle arrest and, in selected tumor contexts, ferroptosis; these effects appear downstream or context-dependent rather than universal initiating mechanisms.</li>
<li>Chemosensitization, radiosensitization and immune-modulatory effects have been demonstrated preclinically, including enhancement of selected targeted therapies and PD-1/PD-L1-directed approaches.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Native honokiol is highly lipophilic and poorly water-soluble, limiting conventional oral and intravenous delivery. It undergoes extensive metabolic clearance, including conjugation, and systemic exposure after ordinary oral formulations may be substantially lower than concentrations commonly used experimentally. Liposomes, nanoemulsions, micelles, nanoparticles and other delivery systems can substantially improve solubility and exposure. A validated pharmacokinetic study of injectable liposomal honokiol has been reported, but clinically established human anticancer PK targets have not yet been defined.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer studies use approximately 10–60 µM honokiol, with some models requiring still higher concentrations. These concentrations should not automatically be considered achievable following conventional oral supplementation because oral bioavailability is limited and human tumor exposure has not been established. The current Phase I lung-cancer study is therefore important for defining human tolerability, systemic exposure and pharmacodynamic effects rather than demonstrating established therapeutic efficacy.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical. Extensive in-vitro and animal anticancer evidence exists across multiple tumor types. Human anticancer efficacy has not been established. A Phase I oral honokiol study in approximately 15 patients with early-stage resectable NSCLC is currently listed by Houston Methodist as enrolling; treatment is given before surgery primarily to determine safety and maximum tolerated dose. Honokiol is not an FDA-approved anticancer drug.</p>
<p><b>Safety / translation:</b> Preclinical toxicology has generally suggested a comparatively broad therapeutic window, but concentrated honokiol should not be assumed equivalent to historical consumption of Magnolia bark preparations. Potential pharmacokinetic interactions, formulation-dependent exposure, and insufficient controlled human safety data remain major translational limitations. FDA records identify Magnolia cortex extract containing honokiol as having been submitted through the New Dietary Ingredient notification process, but this does not constitute approval of honokiol for cancer treatment.</p>
<h3>Honokiol Cancer-Relevant Mechanisms</h3>
<table border="1" cellspacing="0" cellpadding="4">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial Complex I and intrinsic apoptosis</td>
<td>↓ Complex I; ↓ ΔΨm; ↓ respiration; ↑ cytochrome-c; ↑ caspases</td>
<td>↔ or mitochondrial protection (context-dependent)</td>
<td>P/R</td>
<td>Mitochondria-directed cytotoxicity</td>
<td>A particularly strong mechanistic feature of honokiol; mitochondrial accumulation and respiratory inhibition can precede downstream apoptotic signaling.</td>
</tr>
<tr>
<td>2</td>
<td>STAT3 survival and stemness signaling</td>
<td>↓ STAT3; ↓ p-STAT3; ↓ mitochondrial STAT3</td>
<td>↔ (context-dependent)</td>
<td>R/G</td>
<td>Loss of survival, proliferation and stemness signaling</td>
<td>Relevant across several cancer models and linked to reduced CSC phenotype, EMT and resistance.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K AKT mTOR signaling</td>
<td>↓ PI3K; ↓ AKT; ↓ mTOR</td>
<td>↔ or adaptive modulation</td>
<td>R/G</td>
<td>Growth and anabolic suppression</td>
<td>Frequently observed and contributes to apoptosis, metabolic stress and treatment sensitization.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial ROS increase</td>
<td>↑ ROS; ↑ mt-ROS (secondary)</td>
<td>↓ ROS or ↔ (context-dependent)</td>
<td>P/R</td>
<td>Oxidative stress amplification</td>
<td>Cancer-cell ROS elevation often accompanies mitochondrial respiratory disruption. Honokiol can instead act antioxidatively in nonmalignant tissues.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB inflammatory and survival signaling</td>
<td>↓ NF-κB; ↓ COX-2; ↓ inflammatory survival signaling</td>
<td>↓ pathological inflammatory signaling</td>
<td>R/G</td>
<td>Reduced inflammatory and prosurvival transcription</td>
<td>Provides both anticancer and tissue-protective effects depending on cellular context.</td>
</tr>
<tr>
<td>6</td>
<td>EMT invasion and metastasis</td>
<td>↓ EMT; ↓ Snail; ↓ Slug; ↓ MMP2; ↓ MMP9; ↑ E-cadherin</td>
<td>↔</td>
<td>G</td>
<td>Reduced migration, invasion and metastasis</td>
<td>Supported across breast, lung, renal, pancreatic and other tumor models.</td>
</tr>
<tr>
<td>7</td>
<td>Cancer stem cell signaling</td>
<td>↓ CSCs; ↓ CD133; ↓ SOX2; ↓ OCT4; ↓ Nestin; ↓ Wnt/β-catenin</td>
<td>↔</td>
<td>G</td>
<td>Reduced tumor-initiating and resistant cell phenotype</td>
<td>Closely overlaps STAT3, EGFR, Notch and Wnt pathway inhibition.</td>
</tr>
<tr>
<td>8</td>
<td>HIF-1α glycolytic metabolism</td>
<td>↓ HIF-1α; ↓ GLUT1; ↓ HK2; ↓ LDHA; ↓ PDK1; ↓ ECAR; ↓ glycolysis</td>
<td>↔ (context-dependent)</td>
<td>G</td>
<td>Reduced glycolytic flux and ATP production</td>
<td>Especially relevant in glycolysis-dependent and hypoxic tumors.</td>
</tr>
<tr>
<td>9</td>
<td>EGFR and receptor tyrosine kinase signaling</td>
<td>↓ EGFR; ↓ downstream AKT and ERK</td>
<td>↔</td>
<td>R/G</td>
<td>Growth-factor signal suppression</td>
<td>Honokiol can also impair EGFR stability through HDAC6/HSP90-associated mechanisms.</td>
</tr>
<tr>
<td>10</td>
<td>Angiogenesis and hypoxia response</td>
<td>↓ VEGF; ↓ HIF-1α; ↓ angiogenesis</td>
<td>↔</td>
<td>G</td>
<td>Reduced tumor vascular support</td>
<td>Largely downstream of HIF-1α, NF-κB and growth-factor suppression.</td>
</tr>
<tr>
<td>11</td>
<td>ER stress and calcium signaling</td>
<td>↑ ER stress; ↑ GRP78; ↑ CHOP; ↑ Ca²⁺ (model-dependent)</td>
<td>↔ or protective stress response</td>
<td>R/G</td>
<td>Proteotoxic stress and apoptosis</td>
<td>Prominent in selected osteosarcoma and other experimental models rather than universal across cancers.</td>
</tr>
<tr>
<td>12</td>
<td>Cell cycle regulation</td>
<td>↑ G0/G1 or G2/M arrest; ↓ cyclin D1; ↓ CDK2; ↓ CDK4; ↓ CDK6</td>
<td>↔</td>
<td>G</td>
<td>Cytostatic growth suppression</td>
<td>Checkpoint phenotype depends on tumor type and upstream signaling context.</td>
</tr>
<tr>
<td>13</td>
<td>Ferroptosis and lipid peroxidation</td>
<td>↑ ferroptosis; ↑ lipid peroxidation; GPX4 modulation (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Alternative regulated cell death</td>
<td>GPX4 direction is not uniform across studies; HMOX1-associated and GPX4-associated ferroptosis have both been reported.</td>
</tr>
<tr>
<td>14</td>
<td>NRF2 antioxidant response</td>
<td>↔ or ↑ (model-dependent)</td>
<td>↑ NRF2; ↑ antioxidant defenses</td>
<td>R/G</td>
<td>Secondary tissue-protective redox response</td>
<td>NRF2 activation is more compelling as a normal-cell or neuroprotective mechanism than as a core anticancer mechanism.</td>
</tr>
<tr>
<td>15</td>
<td>SIRT3 mitochondrial protection</td>
<td>↑ SIRT3 (context-dependent)</td>
<td>↑ SIRT3; ↑ mitochondrial resilience; ↓ oxidative injury</td>
<td>R/G</td>
<td>Context-dependent mitochondrial regulation</td>
<td>Important for cardioprotective and neuroprotective effects; its cancer role can vary with tumor context because SIRT3 itself has context-dependent tumor biology.</td>
</tr>
<tr>
<td>16</td>
<td>Chemosensitization and targeted-therapy sensitization</td>
<td>↑ treatment sensitivity (drug-dependent)</td>
<td>↔ or tissue protection</td>
<td>G</td>
<td>Combination-treatment enhancement</td>
<td>Preclinical evidence includes chemotherapy, cetuximab, mTOR inhibitors and immune-checkpoint strategies.</td>
</tr>
<tr>
<td>17</td>
<td>Radiosensitization</td>
<td>↑ radiosensitivity (model-dependent)</td>
<td>↔ or radioprotection (context-dependent)</td>
<td>G</td>
<td>Greater radiation response</td>
<td>This apparent duality emphasizes cell type, dose, redox state and treatment timing.</td>
</tr>
<tr>
<td>18</td>
<td>Clinical Translation Constraint</td>
<td>↓ achievable exposure with conventional formulations</td>
<td>Systemic safety incompletely characterized in humans</td>
<td>G</td>
<td>Bioavailability and evidence limitation</td>
<td>Poor aqueous solubility, extensive metabolism, uncertain human tumor exposure and lack of efficacy trials remain central constraints; Phase I investigation is underway.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<p><b>Honokiol and Alzheimer’s disease:</b> Honokiol has meaningful but entirely preclinical relevance to Alzheimer’s disease and related neurodegeneration. Its lipophilicity permits CNS penetration, and experimental studies indicate reductions in oxidative stress, neuroinflammation, excitotoxicity and Aβ-associated toxicity together with preservation of mitochondrial function. SIRT3, NRF2, PPAR/PGC-1α signaling and restoration of microglial metabolic competence are among the more plausible mechanistic axes. No convincing clinical evidence currently establishes honokiol as an AD treatment.</p>
<p><b>Evidence level:</b> Preclinical only. Cell and animal studies support neuroprotective and cognition-related effects, but human AD efficacy, dose-response relationships and long-term neurological safety have not been demonstrated.</p>
<h3>Honokiol Alzheimer’s-Relevant Mechanisms</h3>
<table border="1" cellspacing="0" cellpadding="4">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial function and SIRT3</td>
<td>↑ SIRT3; ↑ mitochondrial function; ↑ ΔΨm</td>
<td>Mitochondrial resilience</td>
<td>One of the strongest mechanistic links between honokiol and neuronal protection.</td>
</tr>
<tr>
<td>2</td>
<td>Oxidative stress and NRF2</td>
<td>↓ ROS; ↑ NRF2; ↑ antioxidant defenses</td>
<td>Reduced oxidative injury</td>
<td>Direction differs from the pro-oxidant stress frequently induced by honokiol in cancer cells.</td>
</tr>
<tr>
<td>3</td>
<td>Microglial metabolism and phagocytosis</td>
<td>↑ PPARα; ↑ PGC-1α; ↑ OXPHOS; ↑ phagocytosis</td>
<td>Improved microglial metabolic function</td>
<td>Experimental evidence suggests reversal of dysfunctional metabolic programming can restore microglial clearance capacity.</td>
</tr>
<tr>
<td>4</td>
<td>Amyloid beta toxicity</td>
<td>↓ Aβ-associated toxicity</td>
<td>Neuroprotection</td>
<td>Supported primarily by experimental models; evidence for modifying human amyloid pathology is absent.</td>
</tr>
<tr>
<td>5</td>
<td>Neuroinflammation</td>
<td>↓ NF-κB; ↓ TNF-α; ↓ IL-1β</td>
<td>Reduced inflammatory injury</td>
<td>Likely overlaps the general anti-inflammatory pharmacology of honokiol.</td>
</tr>
<tr>
<td>6</td>
<td>Excitotoxic calcium signaling</td>
<td>↓ pathological Ca²⁺ signaling</td>
<td>Reduced excitotoxic neuronal injury</td>
<td>Reported neuroprotective actions include modulation of glutamatergic signaling and intracellular calcium overload.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>No demonstrated human AD efficacy</td>
<td>Preclinical evidence only</td>
<td>BBB penetration is pharmacologically favorable but does not establish an effective or safe human CNS dose.</td>
</tr>
</table>